Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

SunGard and TABB research shows boutique fund managers find 'institutionalising' as greatest hurdle

Monday, September 30, 2013

Beverly Chandler, Opalesque London:

According to the second annual edition of research undertaken by research and advisory firm TABB Group and SunGard, 53% of boutique asset management firms identified 'institutionalization’, including the increasing expenses related to regulatory compliance, as the 'make or break’ factor for them over the next 12 months. The report defines this as the growing list of operational and organizational minimum requirements an asset manager must meet in order to attract assets.

The report entitled "Boutique Business Model under Attack: Bruised by Regulation – Crippled by Costs?" reveals that 51% of those surveyed find the institutionalization burden of due diligence and compliance as creating a barrier to entry. This now ranks as the top barrier to entry, moving last year’s top entry, the general cost of setting up operations, to the second spot at 44%.

"Growing operational and regulatory minimum requirements such as AIFMD, Dodd Frank and UCITS IV/V are leaving many boutique asset management firms unable to take part in the mandate process. Scale is the feature that boutiques believe they lack, and technology and better operational efficiency is the key to achieving increased scalability.", commented Adam Sussman, partner and director of research, TABB Group.

......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its